TABLE 2.
Comorbidities, exposures, and clinical characteristics of participants with movement disorders in Cabo Verde, 2024 (N = 110).
| Characteristic | N (%) |
|---|---|
| Comorbidities and exposures | |
| Number of comorbidities (mean ± SD) | 1.3 ± 1.2 |
| No comorbidities | 31 (28.2%) |
| 1–2 comorbidities | 61 (55.5%) |
| >2 comorbidities | 18 (16.4%) |
| Type of comorbidity | |
| Type 1 diabetes | 3 (2.7%) |
| Type 2 diabetes | 23 (20.9%) |
| Diabetes with complications | 3 (2.7%) |
| Hypertension | 59 (53.6%) |
| Hyperlipidaemia | 13 (11.8%) |
| Obesity | 4 (3.6%) |
| Thyroid disorder | 3 (2.7%) |
| Atrial fibrillation | 1 (1.0%) |
| Stroke | 10 (9.1%) |
| Chronic kidney disease | 4 (3.6%) |
| Congestive heart failure | 3 (2.7%) |
| Metastatic cancer | 2 (1.8%) |
| Chronic obstructive pulmonary disease (COPD) | 5 (4.6%) |
| Other comorbidities | 13 (11.8%) |
| Substance use | |
| Tobacco | 10 (9.1%) |
| Alcohol | 20 (18.2%) |
| Illicit drugs | 3 (2.7%) |
| Prescription drug misuse | 9 (8.2%) |
| Exposure to hazardous materials | 19 (34.5%) |
| Iron | 9 (8.2%) |
| Copper | 7 (6.4%) |
| Pesticides | 2 (1.8%) |
| Other | 5 (4.6%) |
| Clinical characteristics | |
| Family history of MD | |
| Yes | 18 (16.4%) |
| No | 32 (30.0%) |
| Don’t know | 15 (13.6%) |
| Not reported | 44 (40.0%) |
| Followed by a neurologist | 93 (90.3%) |
| Type of personal care support | |
| Spouse | 20 (18.2%) |
| Children | 27 (24.6%) |
| Siblings | 4 (3.6%) |
| Grandchildren | 4 (3.6%) |
| Mother | 7 (6.4%) |
| Caregiver | 3 (2.7%) |
| No one | 63 (57.3%) |
SD, standard deviation; COPD, chronic obstructive pulmonary disease; MSA, multiple system atrophy; MD, movement disorder. Percentages may not total 100% due to rounding or missing data.